Q4 2025 ALK-Abello A/S Earnings Call Transcript
Key Points
- Alk-Abello AS (AKBLF) delivered a solid performance in Q4, ending 2025 at the top end of their outlook.
- Revenue in Q4 increased by 17%, driven by strong performance across all geographies, particularly in Europe and North America.
- The company achieved a 25% EBIT margin in 2025, marking a significant improvement from previous years.
- Alk-Abello AS (AKBLF) expanded its patient base significantly, treating 500,000 more patients in 2025, reaching a total of 3.1 million.
- The pediatric rollout of house dust mite and tree pollen tablets has been successful, broadening patient reach and contributing to growth.
- The company faces challenges in the adoption of new anaphylaxis treatments, with established clinical practices favoring traditional methods.
- Pricing adjustments, particularly in France and Germany, could negatively impact revenue growth.
- The departure of the head of R&D raises concerns about potential disruptions in the development pipeline.
- The gross margin is expected to decrease slightly in 2026 due to a less favorable product mix and increased partner-related revenue.
- There are uncertainties regarding the timing and impact of product shipments to China and Japan, which may lead to quarterly fluctuations.
/-
Hello, and welcome to the presentation of ALK's Q4 and full-year 2025 results. My name is Per Plotnikof. I'm Head of Investor Relations and thank you all for joining.
On slide 2, I will present the speakers and agenda for this call. And with me today are CEO, Peter Halling; and CFO, Claus Steensen Sølje. Peter and Claus will walk you through the Q4 and full-year highlights, market and product, as well as the full-year financial performance. Then, we will provide an update on the strategic progress and priorities before presenting our outlook for 2026. As usual, we will end with a Q&A session.
And to get us started, I'll hand you over to Peter and slide number 3. Please go ahead, Peter.
/- -
Thank you, Pierre, and thank you all for joining the call.
We delivered a solid performance in the 4th quarter, leading us to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
